{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:55:22Z","timestamp":1790704522521,"version":"4.1.0"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848101007"],"award-info":[{"award-number":["848101007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejca.2022.07.034","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:46:12Z","timestamp":1662705972000},"page":"60-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review"],"prefix":"10.1016","volume":"175","author":[{"given":"Laurens S.","family":"ter Maat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella A.J.","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd G.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josien P.W.","family":"Pluim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Leiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitko","family":"Veta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karijn P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.07.034_bib1","first-page":"503","article-title":"Ipilimumab (Yervoy) prolongs survival in advanced melanoma","volume":"37","author":"Fellner","year":"2012","journal-title":"Pharm Ther"},{"key":"10.1016\/j.ejca.2022.07.034_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejca.2022.07.034_bib3","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","article-title":"Immunotherapy of melanoma: facts and hopes","volume":"25","author":"Weiss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib6","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.07.034_bib8","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib10","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib13","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.07.034_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40425-018-0344-8","article-title":"Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden","volume":"6","author":"Morrison","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"The \"cancer immunogram\"","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejca.2022.07.034_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2017.00233","article-title":"Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review","volume":"7","author":"Jessurun","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0489-5","article-title":"Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors","volume":"7","author":"Conroy","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2022.07.034_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1007","article-title":"Molecular imaging in drug discovery and development","volume":"2","author":"Rudin","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2022.07.034_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymeth.2020.11.005","article-title":"Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes","volume":"188","author":"Zhang","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.ejca.2022.07.034_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","article-title":"The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis","volume":"48","author":"Ayati","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00259-021-05509-7","article-title":"Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"49","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib23","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/cam4.2709","article-title":"Novel cancer therapies for advanced cutaneous melanoma: the added value of radiomics in the decision making process\u2013a systematic review","volume":"9","author":"Guerrisi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib25","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib26","series-title":"Prognosis research in healthcare: concepts, methods, and impact","author":"Riley","year":"2019"},{"key":"10.1016\/j.ejca.2022.07.034_bib27","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejca.2022.07.034_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ejca.2022.07.034_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib31","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.3390\/cancers13153830","article-title":"Prediction of early response to immune checkpoint inhibition using FDG-PET\/CT in melanoma patients","volume":"13","author":"Kudura","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.07.034_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CJI.0000000000000258","article-title":"Clinical correlates of response to anti-PD-1-based therapy in patients with metastatic melanoma","volume":"42","author":"Davis","year":"2019","journal-title":"J Immunother Hagerstown Md"},{"key":"10.1016\/j.ejca.2022.07.034_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib34","doi-asserted-by":"crossref","first-page":"108688","DOI":"10.1016\/j.ejrad.2019.108688","article-title":"Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy","volume":"121","author":"Schraag","year":"2019","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejca.2022.07.034_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-014-0040-2","article-title":"Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome","volume":"2","author":"Nishino","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib36","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/1759-7714.13214","article-title":"Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"10","author":"Sakata","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib37","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00262-021-03108-x","article-title":"Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 \u2265 50% non-small cell lung cancer patients treated with first-line pembrolizumab","volume":"71","author":"Bureau","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.07.034_bib38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/jcm9030725","article-title":"Potential of FDG-PET as prognostic significance after anti-PD-1 antibody against patients with previously treated non-small cell lung cancer","volume":"9","author":"Hashimoto","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.05.031","article-title":"Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1\/-L1 therapy","volume":"65","author":"Dercle","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib40","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00259-019-04348-x","article-title":"18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer","volume":"46","author":"eige","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib42","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.anl.2020.01.003","article-title":"Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma","volume":"47","author":"Inoue","year":"2020","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.ejca.2022.07.034_bib44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12885-019-5510-y","article-title":"Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography\/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab","volume":"19","author":"Tabei","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cancers13020168","article-title":"A comprehensive analysis of baseline clinical\u00a0characteristics and biomarkers associated with outcome\u00a0in advanced melanoma patients treated with pembrolizumab","volume":"13","author":"Awada","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.07.034_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CJI.0000000000000334","article-title":"Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study","volume":"43","author":"van Zeijl","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2022.07.034_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192227","article-title":"Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial","volume":"13","author":"Tamiya","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejca.2022.07.034_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib50","first-page":"216","volume":"43","author":"Popinat","year":"2019","journal-title":"Med Nucleaire"},{"key":"10.1016\/j.ejca.2022.07.034_bib51","doi-asserted-by":"crossref","first-page":"707050","DOI":"10.3389\/fonc.2021.707050","article-title":"Body composition variables as radiographic biomarkers of clinical outcomes in metastatic renal cell carcinoma patients receiving immune checkpoint inhibitors","volume":"11","author":"Martini","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib52","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/onco.13922","article-title":"Body composition as an independent predictive and prognostic biomarker in advanced urothelial carcinoma patients treated with immune checkpoint inhibitors","volume":"26","author":"Martini","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2022.07.034_bib53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jso.24003","article-title":"Morphomics predicts response to ipilimumab in patients with stage IV melanoma","volume":"112","author":"Sabel","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14740\/wjon1225","article-title":"Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer","volume":"11","author":"Minami","year":"2020","journal-title":"World J Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib55","doi-asserted-by":"crossref","first-page":"109340","DOI":"10.1016\/j.ejrad.2020.109340","article-title":"Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors","volume":"133","author":"Cromb\u00e9","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejca.2022.07.034_bib56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejca.2020.12.028","article-title":"Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: a multi-parametric analysis","volume":"145","author":"Esposito","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib57","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.1038\/s41598-019-46189-6","article-title":"Macroangiopathy is a positive predictive factor for response to immunotherapy","volume":"9","author":"Deike-Hofmann","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.07.034_bib58","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cncr.32576","article-title":"Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials","volume":"126","author":"Martini","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib59","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/1759-7714.14142","article-title":"Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy","volume":"12","author":"Araki","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib60","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00432-020-03146-5","article-title":"Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors","volume":"146","author":"Takada","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib61","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non\u2013small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.07.034_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.699668","article-title":"Predictive value of skeletal muscle mass in recurrent\/metastatic head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors","volume":"11","author":"Arribas","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib63","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/CAD.0000000000000982","article-title":"Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report","volume":"31","author":"Fukushima","year":"2020","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2022.07.034_bib64","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/diagnostics10050310","article-title":"Clinical impact of sarcopenia and inflammatory\/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with pembrolizumab","volume":"10","author":"Shimizu","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejca.2022.07.034_bib65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10120-020-01124-x","article-title":"Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors","volume":"24","author":"Kim","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib66","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41598-020-58498-2","article-title":"Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: a multicenter real-life study","volume":"10","author":"Cortellini","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.07.034_bib67","doi-asserted-by":"crossref","first-page":"e000821","DOI":"10.1136\/jitc-2020-000821","article-title":"Impact of body composition on outcomes from anti-PD1 +\/\u2212 anti-CTLA-4 treatment in melanoma","volume":"8","author":"Young","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1759-7714.12965","article-title":"Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: a \"hypothesis-generator\" preliminary report","volume":"10","author":"Cortellini","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib69","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.2147\/CMAR.S210958","article-title":"Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients","volume":"11","author":"Magri","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cam4.3631","article-title":"Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer","volume":"10","author":"Nishioka","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib71","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3390\/jcm10071361","article-title":"Progressive sarcopenia correlates with poor response and outcome to immune checkpoint inhibitor therapy","volume":"10","author":"Loosen","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib72","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clnesp.2021.01.009","article-title":"Myosteatosis is prognostic in metastatic melanoma treated with nivolumab","volume":"42","author":"Youn","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.ejca.2022.07.034_bib73","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib75","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/cam4.2807","article-title":"Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status","volume":"9","author":"Adachi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non\u2013small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2022.07.034_bib77","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12149-020-01539-7","article-title":"FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer","volume":"34","author":"Seban","year":"2020","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib78","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","volume":"19","author":"Bilen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/bjc.2017.480","article-title":"Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials","volume":"118","author":"Sen","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/vaccines8020203","article-title":"The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy","volume":"8","author":"Botticelli","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.ejca.2022.07.034_bib81","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2967\/jnumed.120.254482","article-title":"Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET\/CT in patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"62","author":"Nakamoto","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib82","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/CJI.0000000000000204","article-title":"Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices","volume":"41","author":"Cowey","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2022.07.034_bib83","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","article-title":"Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT","volume":"44","author":"Nobashi","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib84","doi-asserted-by":"crossref","first-page":"13362","DOI":"10.1038\/s41598-019-50079-2","article-title":"18F-FDG uptake in PET\/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer","volume":"9","author":"Takada","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.07.034_bib85","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib86","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2214\/AJR.18.19796","article-title":"Tumor heterogeneity on FDG PET\/CT and immunotherapy: an imaging biomarker for predicting treatment response in patients with metastatic melanoma","volume":"212","author":"Sanli","year":"2019","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.ejca.2022.07.034_bib87","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/MNM.0000000000001025","article-title":"18F-FDG PET\/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy","volume":"40","author":"Evangelista","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ejca.2022.07.034_bib88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","article-title":"18F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma","volume":"20","author":"Wong","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib89","doi-asserted-by":"crossref","first-page":"728040","DOI":"10.3389\/fonc.2021.728040","article-title":"Positron emission tomography-computed tomography parameters predict efficacy of immunotherapy in head and neck squamous cell carcinomas","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib90","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cllc.2021.03.001","article-title":"The value of 18F-FDG PET\/CT in predicting the response to PD-1 blocking immunotherapy in advanced NSCLC patients with high-level PD-L1 expression","volume":"22","author":"Vekens","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib91","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.21037\/jtd.2019.04.41","article-title":"Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors","volume":"11","author":"Ichiki","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2022.07.034_bib92","doi-asserted-by":"crossref","first-page":"18795","DOI":"10.1038\/s41598-021-98310-3","article-title":"FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy","volume":"11","author":"Flaus","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.07.034_bib93","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","article-title":"Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib94","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00259-019-04483-5","article-title":"18F-Sodium fluoride PET\/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab","volume":"47","author":"Lim","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib95","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-019-0516-1","article-title":"FLT PET\/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab","volume":"7","author":"Scarpelli","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib96","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib97","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","article-title":"89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer","volume":"33","author":"Kok","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib98","first-page":"927","article-title":"First-in-human study of 89Zr-pembrolizumab PET\/CT in patients with advanced stage non-small-cell lung cancer","volume":"56","author":"Niemeijer","year":"2021","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.034_bib99","first-page":"2197","article-title":"PD-L1 PET\/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer","volume":"25","author":"Smit","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib100","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1007\/s00259-021-05407-y","article-title":"Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy","volume":"48","author":"van de Donk","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib101","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2967\/jnumed.121.262368","article-title":"18F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study","volume":"63","author":"Nienhuis","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib102","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/neuonc\/noz141","article-title":"MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors","volume":"21","author":"Bhatia","year":"2019","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib103","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1007\/s00330-018-5933-x","article-title":"Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab","volume":"29","author":"Durot","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2022.07.034_bib104","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1541-7786.MCR-20-1038","article-title":"Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients","volume":"19","author":"Aoude","year":"2021","journal-title":"Mol Cancer Res MCR"},{"key":"10.1016\/j.ejca.2022.07.034_bib105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.diii.2021.09.009","article-title":"CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma: CT texture analysis of metastatic skin melanoma","volume":"103","author":"Bonnin","year":"2021","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejrad.2019.07.019","article-title":"Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: a multicentre retrospective study","volume":"118","author":"Ravanelli","year":"2019","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejca.2022.07.034_bib107","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1038\/s41598-021-86113-5","article-title":"CT based radiomic approach on first line pembrolizumab in lung cancer","volume":"11","author":"Zerunian","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.07.034_bib108","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-19-2942","article-title":"Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics","volume":"26","author":"Dercle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib109","first-page":"e242","article-title":"Metastatic clear-cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab: Nivomics 01-study","volume":"203","author":"Khene","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2022.07.034_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104916","article-title":"Immunotherapy treatment outcome prediction in metastatic melanoma through an automated multi-objective delta-radiomics model","volume":"138","author":"Chen","year":"2021","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib111","doi-asserted-by":"crossref","first-page":"657615","DOI":"10.3389\/fonc.2021.657615","article-title":"Imaging biomarkers to predict and evaluate the effectiveness of immunotherapy in advanced non-small-cell lung cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003261","article-title":"A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma","volume":"9","author":"Brendlin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib113","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3389\/fonc.2020.01524","article-title":"Pilot study of CT-based radiomics model for early evaluation of response to immunotherapy in patients with metastatic melanoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib114","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdz108","article-title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","volume":"30","author":"Trebeschi","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib115","doi-asserted-by":"crossref","first-page":"544339","DOI":"10.3389\/fonc.2021.544339","article-title":"A CT-based radiomics approach to predict nivolumab response in advanced non-small-cell lung cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib116","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41416-021-01375-0","article-title":"Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"125","author":"Mu","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib117","doi-asserted-by":"crossref","DOI":"10.1148\/ryai.2019190063","article-title":"Radiomics of 18F fluorodeoxyglucose PET\/CT images predicts severe immune-related adverse events in patients with NSCLC","volume":"2","author":"Mu","year":"2020","journal-title":"Radiol Artif Intell"},{"key":"10.1016\/j.ejca.2022.07.034_bib118","first-page":"1559","article-title":"Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab","volume":"19","author":"Nardone","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejca.2022.07.034_bib119","article-title":"Pre-immunotherapy contrast-enhanced CT texture-based classification: a useful approach to non-small cell lung cancer immunotherapy efficacy prediction","volume":"11","author":"Shen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib120","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01780-2","article-title":"Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer","volume":"22","author":"Yang","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib121","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00262-020-02810-6","article-title":"A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC","volume":"70","author":"Del Re","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.07.034_bib122","doi-asserted-by":"crossref","DOI":"10.2217\/lmt-2020-0002","article-title":"Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer","volume":"9","author":"Ladwa","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.ejca.2022.07.034_bib123","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-5806","article-title":"Hypoxia-related radiomics predict checkpoint blockade immunotherapy response of nonsmall cell lung cancer patients","volume":"80","author":"Tunali","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib124","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2478\/raon-2020-0042","article-title":"[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab","volume":"54","author":"Valentinuzzi","year":"2020","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163992","article-title":"Preliminary report on computed tomography radiomics features as biomarkers to immunotherapy selection in lung adenocarcinoma patients","volume":"13","author":"Granata","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.07.034_bib126","article-title":"A CT-based radiomic signature can be prognostic for 10-months overall survival in metastatic tumors treated with Nivolumab: an exploratory study","volume":"11","author":"Corino","year":"2021","journal-title":"Diagn Basel Switz"},{"key":"10.1016\/j.ejca.2022.07.034_bib127","doi-asserted-by":"crossref","first-page":"734872","DOI":"10.3389\/fonc.2021.734872","article-title":"Predictive value of multiparametric MRI for response to single-cycle induction chemo-immunotherapy in locally advanced head and neck squamous cell carcinoma","volume":"11","author":"Hellwig","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib128","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1007\/s00330-020-06847-0","article-title":"Radiomics-based prediction model for outcomes of PD-1\/PD-L1 immunotherapy in metastatic urothelial carcinoma","volume":"30","author":"Park","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2022.07.034_bib129","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.euo.2019.02.002","article-title":"Predictive role of computed tomography texture analysis in patients with metastatic urothelial cancer treated with programmed death-1 and programmed death-ligand 1 inhibitors","volume":"3","author":"Alessandrino","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib130","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s00345-020-03334-5","article-title":"Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept","volume":"39","author":"Khene","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.ejca.2022.07.034_bib131","first-page":"e924671","article-title":"Use of radiomics to predict response to immunotherapy of malignant tumors of the digestive system","volume":"26","author":"Ji","year":"2020","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib132","article-title":"Computed tomography-derived radiomic metrics can identify responders to immunotherapy in ovarian cancer","volume":"3","author":"Himoto","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib133","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1186\/s12885-021-08899-x","article-title":"Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive radiomic biomarkers","volume":"21","author":"Zhu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib134","doi-asserted-by":"crossref","first-page":"613946","DOI":"10.3389\/fimmu.2020.613946","article-title":"Development and validation of a contrast-enhanced CT-based radiomics nomogram for prediction of therapeutic efficacy of anti-PD-1 antibodies in advanced HCC patients","volume":"11","author":"Yuan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2022.07.034_bib135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijrobp.2020.06.026","article-title":"A validated T cell radiomics score is associated with clinical outcomes following multisite SBRT and pembrolizumab","volume":"108","author":"Korpics","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.07.034_bib136","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10637-017-0524-2","article-title":"Radiomics to predict immunotherapy-induced pneumonitis: proof of concept","volume":"36","author":"Colen","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2022.07.034_bib137","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1148\/radiol.2021200928","article-title":"A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors","volume":"299","author":"Ligero","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2022.07.034_bib138","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib139","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001429","article-title":"Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells","volume":"8","author":"Sun","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/jimaging6120133","article-title":"3D non-local neural network: a non-invasive biomarker for immunotherapy treatment outcome prediction. case-study: metastatic urothelial carcinoma","volume":"6","author":"Rundo","year":"2020","journal-title":"J Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib141","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.clgc.2021.03.012","article-title":"Three-dimensional deep noninvasive radiomics for the prediction of disease control in patients with metastatic urothelial carcinoma treated with immunotherapy","volume":"19","author":"Rundo","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib142","doi-asserted-by":"crossref","first-page":"10838","DOI":"10.7150\/thno.50283","article-title":"Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma","volume":"10","author":"Park","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejca.2022.07.034_bib143","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000550","article-title":"Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker","volume":"8","author":"He","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib144","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19116-x","article-title":"Non-invasive decision support for NSCLC treatment using PET\/CT radiomics","volume":"11","author":"Mu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2022.07.034_bib145","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.7150\/thno.48027","article-title":"Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images","volume":"11","author":"Tian","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejca.2022.07.034_bib146","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/SLA.0000000000002064","article-title":"The tumor burden score: a new \"Metro-ticket\" prognostic tool for colorectal liver metastases based on tumor size and number of tumors","volume":"267","author":"Sasaki","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2022.07.034_bib147","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1097-0142(19880415)61:8<1719::AID-CNCR2820610834>3.0.CO;2-A","article-title":"Tumor burden as the most important prognostic factor in early stage Hodgkin\u2019s disease. Relations to other prognostic factors and implications for choice of treatment","volume":"61","author":"Specht","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.07.034_bib148","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1200\/JCO.2001.19.5.1388","article-title":"Image-aided estimate of tumor burden in Hodgkin\u2019s disease: evidence of its primary prognostic importance","volume":"19","author":"Gobbi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib149","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3390\/cells9040992","article-title":"Hypoxia-driven immune escape in the tumor microenvironment","volume":"9","author":"Vito","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2022.07.034_bib150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-020-02667-4","article-title":"Hypoxia and the phenomenon of immune exclusion","volume":"19","author":"Pietrobon","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib151","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","article-title":"Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy","volume":"40","author":"Wang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib152","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non\u2013small cell lung cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib153","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1470-2045(19)30797-1","article-title":"Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study","volume":"21","author":"Sanchez","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib154","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib155","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab exposure\u2013response assessments challenged by association of cancer cachexia and catabolic clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.07.034_bib156","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jso.24025","article-title":"The impact of sarcopenia on survival and complications in surgical oncology: a review of the current literature","volume":"112","author":"Joglekar","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.07.034_bib157","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40644-019-0270-0","article-title":"CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis","volume":"19","author":"Su","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ejca.2022.07.034_bib158","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jcsm.12258","article-title":"Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition?","volume":"9","author":"N\u00ed Bhuachalla","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejca.2022.07.034_bib159","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib160","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.07.034_bib161","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/RLI.0000000000000180","article-title":"Measuring CT scanner variability of radiomics features","volume":"50","author":"Mackin","year":"2015","journal-title":"Invest Radiol"},{"key":"10.1016\/j.ejca.2022.07.034_bib162","doi-asserted-by":"crossref","first-page":"e048008","DOI":"10.1136\/bmjopen-2020-048008","article-title":"Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence","volume":"11","author":"Collins","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2022.07.034_bib163","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:28Z","timestamp":1760733448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922004798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":163,"alternative-id":["S0959804922004798"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}